Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.64 |
| ▸ | CDK2 | P24941 | 8/20 | 0.64 |
| ▸ | PRKCA | P17252 | 2/20 | 0.64 |
| ▸ | CLK1 | P49759 | 4/20 | 0.53 |
| ▸ | CLK2 | P49760 | 4/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445788 | 1.00 | CDK1 (0.72) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3445648 | 0.89 | CDK1 (0.56) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3445218 | 0.89 | CDK2 (0.62) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3446815 | 0.89 | CDK2 (0.61) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3444708 | 0.88 | CDK1 (0.67) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3445283 | 0.86 | CDK1 (0.54) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3444440 | 0.86 | CDK1 (0.54) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3445138 | 0.86 | CLK1 (0.73) | CDK1CCNE1CDK2PRKCACLK1 | |
| SCHEMBL3445975 | 0.85 | CDK1 (0.72) | CDK1PDGFRACCNE1CDK2PRKCA | |
| SCHEMBL3444543 | 0.83 | FLT3 (0.70) | CDK1PDGFRACCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816350-B2 | Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2010-10-19 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | CDK1 3/4885PDGFRA 1923/4885CCNE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.